Developer docs
API playgroundTry for free, no card

Search company profiles

Prodo Laboratories

Full company profile

uuid002b4pl

Namestring
Prodo Laboratories
Legal namestring
Prodo Laboratories, Inc.
Websiteurl
prodolabs.com
Company typeenum
Private
Founded yearint
2006
Descriptiontext

Prodo Laboratories, Inc. is a privately held, Delaware-incorporated diabetes biotechnology and services company founded in 2006 by Dr. David Scharp and headquartered in Aliso Viejo, California (relocated from an Irvine R&D facility in January 2016). The company processes and supplies high-quality human and animal islets to the diabetes research community, serving biotechnology and pharmaceutical companies for in vitro and in vivo drug development, as well as academic and government-funded investigators (JDRF, NIH/NIDDK). Human research pancreases are sourced through contracts with Organ Procurement Organizations from UNOS-listed cadaver donors refused for primary transplantation, with the company demonstrating the ability to process highly purified islets (85–90% purity, ~95% viability) even from donors with extended cold ischemia times (~14 hours average).

The company's core technology is its proprietary cGMP Prodo Islet Media (PIM®) product line, developed specifically for islet recovery, culture, and transport: PIM(R)® for the first 48 hours of recovery, PIM(S)® for long-term culture (2–21 days), and PIM(T)® for cold storage/shipping (3–4 days), supported by required supplements PIM(ABS)® (Human AB Serum), PIM(G)® (Glutamine/Glutathione), and PIM(3X)® (triple antibiotic mixture), available individually or bundled as PIM Complete. The media carries an FDA Biological Master File (IND-15016) granted in March 2012 and has been shown to outperform CRML-based media in University of Pittsburgh testing.

Prodo monetizes through multiple streams: transaction-based Human Islets for Research (HIR) service contracts (Preferred Recipients receive monthly volumes at lower pricing and higher priority; Ad Hoc Recipients order as-needed), sale of proprietary cGMP PIM media products, contract research services (assays, human and animal islet processing, and Scharp consulting), and the Islet Testing Authority (ITA) certification service operated through the affiliated Scharp-Lacy Research Institute. Go-to-market is sales-led via direct corporate contracts and academic distribution through Scharp-Lacy (JDRF, NIDDK IIDP, where Prodo is the sole corporate laboratory partner), with international reach through distributors in Japan (Eolas Biosciences) and Europe (Tebubio, Tissue Solutions). The company employs 11–50 people and has been funded via a $300,000 SBA loan (2007) and NIH/SBIR and QTDG grants rather than venture capital.

Short descriptiontext

Prodo Laboratories is a diabetes biotechnology service company supplying high-quality human and animal islets and proprietary cGMP islet culture media (PIM®) to biotechnology, pharmaceutical, academic, and government-funded diabetes researchers for drug development and transplantation research.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersAliso Viejo, United States
HQ citystring
Aliso Viejo
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
human islets supply, islet culture media, diabetes research services, cGMP media products, animal islet isolation
Industry1 code
PRIMARYHLAGANAB
Proteomics & Mass Spectrometry Services
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Specialty Lab Services (Genomics/Proteomics/Cellomics)
NAICS code1 code
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code1 code
  • In Vitro & In Vivo Diagnostic Substances2835
Product category
Diabetes Research Services & Islet Supply
No data
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model4 records
1Human Islets for Research (HIR)
TypeTransaction Fee
Description

Direct service business providing high quality human islets to biotechnology and pharmaceutical companies for in vitro and in vivo testing in diabetes drug development. Also provides human islets from Type 2 diabetes donors. Islets held on tissue culture for 2-3 days for quality assurance before shipping.

prodolabs.com
2cGMP Prodo Islet Media Products
TypeOne Time License
Description

Sale of proprietary cGMP islet culture media (PIM(R), PIM(S), PIM(T)) and supplements. Products available individually or as simplified PIM Complete bundles.

prodolabs.com
3Contract Research Services
TypeProfessional Services
Description

Assays, islet processing, and consulting services. Includes human islet processing, animal islet processing (porcine, rat), and Scharp Consulting.

prodolabs.com
4Islet Testing Authority (ITA)
TypeProfessional Services
Description

Testing and certification service for tissue culture media, factors, reagents, pancreas processing solutions, enzymes, and reagents. Division of Scharp-Lacy Research Institute.

prodolabs.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels4 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Personnel, Operations, Technology or R&D, Supply Chain, Marketing or Sales, Infrastructure
Pricing details3 tiers
1PIM Complete - simplified ordering option
ModelOne time/ perpetual licenseBilling cadencePay-as-you-go
Notes

Single catalog number for base medium (R-Recovery, S-Standard, or T-Transport) plus all required supplements (ABS-Human AB Serum, G-Glutamine/Glutathione, 3X-Triple Antibiotics)

prodolabs.com
2Preferred Recipient pricing for corporate clients
ModelTransaction based/ take rateBilling cadenceMonthly
Notes

Designated for corporate investigators establishing monthly specified amounts of human islets. Lower pricing and higher priority for receiving available human islets compared to Ad Hoc Recipients.

prodolabs.com
3Ad Hoc Recipient pricing for irregular orders
ModelTransaction based/ take rateBilling cadencePay-as-you-go
Notes

For corporate investigators requesting human islets on an as-needed basis. Standard pricing with lower priority for islet availability.

prodolabs.com
GTM typeB2B
B2B
Offering typeServices
Services
Brand1 of 4 records shown
1Prodo Islet Media (PIM)
Description

cGMP islet media product line including PIM(R) for recovery, PIM(S) for standard culture, and PIM(T) for transport.

prodolabs.com
+3 more records
Core offering1 text field

Prodo Laboratories operates a service business providing high-quality human pancreatic islets (including normal and Type 2 diabetes donor islets) to biotechnology and pharmaceutical companies for in vitro and in vivo diabetes drug development testing, and to academic and government-funded researchers for diabetes research. It also produces and sells a proprietary cGMP islet culture media product line (Prodo Islet Media / PIM®) — including recovery, standard culture, and transport media plus required supplements — used by islet researchers globally.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • Purity averaging 85-90% and viability averaging 95% for shipped human islets
+2 more records
Product overview1 text field

Prodo Laboratories is a biotechnology company providing a comprehensive portfolio of products and services for the diabetes research community. The core offering consists of the proprietary cGMP Prodo Islet Media (PIM®) product line, which includes three specialized media formulations—PIM(R)® for recovery, PIM(S)® for standard long-term culture, and PIM(T)® for transport/cold storage—along with required supplements PIM(ABS)® (Human AB Serum), PIM(G)® (Glutamine/Glutathione), and PIM(3X)® (Triple Antibiotics), available individually or as the combined PIM Complete solution. The company also provides Human Islets for Research (HIR) as its primary service, Animal Islets for Research (AIR) including rodent and porcine preparations, and the Islet Testing Authority (ITA) certification service for testing biological reagents on human islets. Contract research services and scientific consulting from Dr. David Scharp complement the product portfolio.

Product and service9 records
1PIM(R)® — Islet Recovery Medium
CategorycGMP Islet Culture Media
Description

Islet-specific recovery medium manufactured under cGMP conditions, designed for the first 48 hours of tissue culture at 37°C to accelerate recovery of islets following processing and purification. Demonstrates rapid rounding up with increased glucose responsiveness, insulin content, and suitability for implantation. Contains 5.8 mM glucose and no animal proteins or growth factors. For diabetes researchers using Prodo Labs' islet supply or third-party islets.

2PIM(S)® — Standard Culture Medium
CategorycGMP Islet Culture Media
Description

Islet-specific standard culture medium manufactured under cGMP conditions for long-term tissue culture of islets from 2 to 21 days at 37°C. Enhanced with specific components that maintain glucose responsiveness, insulin content, and suitability for implantation. Contains 5.8 mM glucose and 5% Human AB Serum, with no animal proteins or growth factors. For diabetes researchers requiring extended islet culture.

3PIM(T)® — Transport Medium
CategorycGMP Islet Culture Media
Description

Proprietary islet medium manufactured under cGMP for cold storage of isolated islets, permitting both short and long-term islet shipping and storage. Provides 3-4 days of cold storage without loss of islet compactness and supports long-term cold tissue culture for approximately 3 weeks. Islets can be directly transferred to tissue culture incubator at 37°C without media removal. For researchers needing to ship or store islets.

4PIM(ABS)® — Human AB Serum Supplement
CategorycGMP Islet Culture Supplement
Description

Required cGMP additive for PIM(R), PIM(S), and PIM(T) islet-specific tissue culture media. Human AB serum collected, screened, and frozen until cGMP manufacturing, including heat inactivation and sterile filtration. All lots screened for compatibility with human islets prior to release. For diabetes researchers using PIM media.

5PIM(G)® — Glutamine/Glutathione Supplement
CategorycGMP Islet Culture Supplement
Description

Required cGMP additive for PIM(R), PIM(S), and PIM(T) islet-specific tissue culture media. Shipped separately as a frozen component to permit extended shelf life. For diabetes researchers using PIM media.

6PIM(3X)® — Triple Antibiotic Supplement
CategorycGMP Islet Culture Supplement
Description

cGMP triple antibiotic mixture required to supplement PIM(R), PIM(S), and PIM(T) for islet culture. Shipped separately as a frozen component to permit extended shelf life. For diabetes researchers using PIM media requiring contamination control.

7PIM Complete
CategorycGMP Islet Culture Media Bundle
Description

Simplified ordering solution combining base medium (PIM(R)® for Recovery, PIM(S)® for Standard, or PIM(T)® for Transport) and all required supplements (PIM(ABS)® Human AB Serum, PIM(G)® Glutamine/Glutathione, PIM(3X)® Triple Antibiotics) under a single catalog number. For diabetes researchers purchasing the full PIM media system.

8Human Islets for Research (HIR)
CategoryPrimary Research Service
Description

Primary service business providing high quality human islets to biotechnology and pharmaceutical companies for in vitro and in vivo testing in diabetes drug development, and to academic and government-funded researchers for diabetes research. Islets sourced from cadaver organ donors with documented informed consent, processed to documented purity of 85-90% and viability of 95%. Includes Type 2 diabetes donor islets (added October 2010). Islets held on tissue culture for 2-3 days for quality assurance before shipping. Available as Preferred Recipient (monthly specified amounts, lower pricing, higher priority) or Ad Hoc Recipient (as-needed) arrangements.

9Animal Islets for Research (AIR)
Scale indicator8 records

Each record includes

Type, Value, Description, Source

Partnership8 partners
Strategic tierCoreTypeChannel Partner/ Reseller/ Distributor
Description

Exclusive distributor for Prodo Labs products (islets and media) in Japan. Located at 2-21-18 Kita-Matsudo, Matsudo-shi, Chiba Prefecture 271-0063, Japan. Contact: TEL: +81-47-308-2204, FAX: +81-47-308-2104, www.eolas-bio.co.jp

2Tebubio (Europe)
Strategic tierCoreTypeChannel Partner/ Reseller/ Distributor
Description

Multi-country European distributor network covering Belgium, Luxembourg, France, Germany, Austria, Switzerland, Italy, Netherlands, Portugal, Spain, UK, Ireland, and Rest of Europe. Offices include Tebubio Belgium & Luxembourg (Lier), Tebubio Sas-France (Le Perray En Yvelines), Tebubio Germany/Austria/Switzerland (Offenbach), Tebubio Italy (Magenta), Tebubio Netherlands (Heerhugowaard), Tebubio Portugal (Lisboa), Tebubio Spain (Barcelona), Tebubio UK & Ireland (Peterborough).

prodolabs.com
3Tissue Solutions, Ltd.
Strategic tierMinorTypeChannel Partner/ Reseller/ Distributor
Description

UK-based distributor for Prodo Labs products. Located at Suite 1.2 First Floor, Fleming Pavilion, Todd Campus, West of Scotland Science Park, Glasgow, G20 0XA. Tel: +44 (0)141 299 0055.

prodolabs.com
4Scharp-Lacy Research Institute (SLRI)
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Collaborative partnership where SLRI handles academic distribution of human islets to JDRF and NIDDK funded researchers. SLRI's Islet Testing Authority (ITA) division provides testing and certification services for tissue culture media, reagents, and processing solutions. Formerly known as Invenio Institute; name changed in June 2008 to honor Paul Lacy and David Scharp's collaborative research history.

prodolabs.com
5National Institute for Diabetes, Digestive, and Kidney Diseases (NIDDK)
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Partnership through Interactive Islet Distribution Program (IIDP). Prodo Labs is the only corporate laboratory partner, collaborating with SLRI to supply human islets to NIDDK funded diabetes investigators.

prodolabs.com
Strategic tierCoreTypeStrategic or Co-development Partner
Description

JDRF contracted with Invenio Institute (now SLRI) to distribute human islets to JDRF funded investigators. Prodo Labs processes the human islets for this distribution program. Distributed 5 million human islets during first contract in 2007.

Strategic tierCoreTypeOthers
Description

Contracts with specific Organ Procurement Organizations to deliver human research pancreases from UNOS listed cadaver organ donors refused for primary transplantation. Required criteria include freedom from specific diseases, appropriate blood test and drug screen results.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Dr. Scharp trained and worked at Washington University for nearly 30 years. Collaborative studies with late Paul E. Lacy pioneered early progress in islet transplantation. Company founders maintain academic research connections.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeEmerging player
Description

Develops Cell Pouch System for islet transplantation in Type 1 diabetes. Adjacent player in diabetes cell therapy research that uses human islets for preclinical testing, creating indirect customer relationship with Prodo Labs' islet supply service.

TypeBroad incumbent
Description

Major life science tools company producing cell culture media, reagents, and laboratory consumables through brands like Gibco. Overlaps with Prodo Labs' media product line but serves far broader research markets with greater resources and distribution scale.

TypeBroad incumbent
Description

Global leader in cell and gene therapy manufacturing services and cell culture media production. Comparable to Prodo Labs as a broad incumbent providing cell-based services and biological products to pharma/biotech, though Lonza operates across many therapeutic areas rather than specializing in islets.

TypeDirect peer
Description

Provides primary human cells, animal cells, and specialized cell culture media for research applications. Direct peer offering comparable cell-based products and culture media to diabetes and broader biomedical research markets.

TypeDirect peer
Description

Specializes in cell culture media, primary cells, and tissue-specific reagents for life science research. Direct peer to Prodo Labs' islet media business with comparable specialized cell biology products serving research customers.

6ViaCyte
TypeEmerging player
Description

Develops stem cell-derived islet cell replacement therapies for Type 1 diabetes. While not a direct service competitor, ViaCyte's stem cell-derived beta cells represent a future alternative to cadaver-derived human islets that Prodo Labs supplies for research.

TypeBroad incumbent
Description

Global life science tools giant producing cell culture media, reagents, and laboratory consumables. Competes broadly with Prodo Labs' media products while serving vastly larger and more diversified research customer base.

TypeDirect peer
Description

Manufactures cell culture media, cytokines, and reagents for cell and gene therapy applications. Comparable to Prodo Labs' cGMP media manufacturing with focus on regulated cell therapy markets and pharmaceutical customers.

9Beta-O2 Technologies
TypeEmerging player
Description

Develops encapsulated pancreatic beta cell implants (βAir) for Type 1 diabetes treatment. Operates in the diabetes cell therapy space that intersects with Prodo Labs' human islet research services and shares the same end-research customer base.

TypeDirect peer
Description

Provides human biospecimens, including tissues and cells, for biomedical research and drug development. Direct peer offering comparable human tissue procurement, processing, and distribution services to pharma/biotech customers similar to Prodo Labs' islet supply business.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses2 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers3 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile5 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature6 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles3 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries1 record

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance2 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Prodo Laboratories

Diabetes Research Services & Islet Supplyprodolabs.com

Prodo Laboratories is a diabetes biotechnology service company supplying high-quality human and animal islets and proprietary cGMP islet culture media (PIM®) to biotechnology, pharmaceutical, academic, and government-funded diabetes researchers for drug development and transplantation research.

What Prodo Laboratories does

Prodo Laboratories, Inc. is a privately held, Delaware-incorporated diabetes biotechnology and services company founded in 2006 by Dr. David Scharp and headquartered in Aliso Viejo, California (relocated from an Irvine R&D facility in January 2016). The company processes and supplies high-quality human and animal islets to the diabetes research community, serving biotechnology and pharmaceutical companies for in vitro and in vivo drug development, as well as academic and government-funded investigators (JDRF, NIH/NIDDK). Human research pancreases are sourced through contracts with Organ Procurement Organizations from UNOS-listed cadaver donors refused for primary transplantation, with the company demonstrating the ability to process highly purified islets (85–90% purity, ~95% viability) even from donors with extended cold ischemia times (~14 hours average).

The company's core technology is its proprietary cGMP Prodo Islet Media (PIM®) product line, developed specifically for islet recovery, culture, and transport: PIM(R)® for the first 48 hours of recovery, PIM(S)® for long-term culture (2–21 days), and PIM(T)® for cold storage/shipping (3–4 days), supported by required supplements PIM(ABS)® (Human AB Serum), PIM(G)® (Glutamine/Glutathione), and PIM(3X)® (triple antibiotic mixture), available individually or bundled as PIM Complete. The media carries an FDA Biological Master File (IND-15016) granted in March 2012 and has been shown to outperform CRML-based media in University of Pittsburgh testing.

Prodo monetizes through multiple streams: transaction-based Human Islets for Research (HIR) service contracts (Preferred Recipients receive monthly volumes at lower pricing and higher priority; Ad Hoc Recipients order as-needed), sale of proprietary cGMP PIM media products, contract research services (assays, human and animal islet processing, and Scharp consulting), and the Islet Testing Authority (ITA) certification service operated through the affiliated Scharp-Lacy Research Institute. Go-to-market is sales-led via direct corporate contracts and academic distribution through Scharp-Lacy (JDRF, NIDDK IIDP, where Prodo is the sole corporate laboratory partner), with international reach through distributors in Japan (Eolas Biosciences) and Europe (Tebubio, Tissue Solutions). The company employs 11–50 people and has been funded via a $300,000 SBA loan (2007) and NIH/SBIR and QTDG grants rather than venture capital.

Prodo Laboratories firmographics

Firmographics
Name
Prodo Laboratories
Legal name
Prodo Laboratories, Inc.
Website
https://prodolabs.com
Company type
Private
Founded year
2006
Operating status
Operating
Headcount range
11–50 employees
Short description
Prodo Laboratories is a diabetes biotechnology service company supplying high-quality human and animal islets and proprietary cGMP islet culture media (PIM®) to biotechnology, pharmaceutical, academic, and government-funded diabetes researchers for drug development and transplantation research.
Ownership category
akta.pro rank

Prodo Laboratories industry classification

Industry
Product category
Diabetes Research Services & Islet Supply
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
In Vitro & In Vivo Diagnostic Substances (2835)
akta.pro industry
PRIMARYHLAGANAB
Proteomics & Mass Spectrometry Services
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Specialty Lab Services (Genomics/Proteomics/Cellomics)

Keywords

  • Human islets supply
  • Islet culture media
  • Diabetes research services
  • CGMP media products
  • Animal islet isolation

Where Prodo Laboratories is headquartered

Location

Headquarters

HQ city
Aliso Viejo
HQ country
United States
HQ region
North America

Offices2 records

Markets served

Prodo Laboratories business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations, Technology or R&D, Supply Chain, Marketing or Sales, Infrastructure

Revenue model

  1. Human Islets for Research (HIR): Direct service business providing high quality human islets to biotechnology and pharmaceutical companies for in vitro and in vivo testing in diabetes drug development. Also provides human islets from Type 2 diabetes donors. Islets held on tissue culture for 2-3 days for quality assurance before shipping.
  2. cGMP Prodo Islet Media Products: Sale of proprietary cGMP islet culture media (PIM(R), PIM(S), PIM(T)) and supplements. Products available individually or as simplified PIM Complete bundles.
  3. Contract Research Services: Assays, islet processing, and consulting services. Includes human islet processing, animal islet processing (porcine, rat), and Scharp Consulting.
  4. Islet Testing Authority (ITA): Testing and certification service for tissue culture media, factors, reagents, pancreas processing solutions, enzymes, and reagents. Division of Scharp-Lacy Research Institute.

Pricing tiers

ModelBillingPrice
One time/ perpetual licensePay-as-you-goPIM Complete - simplified ordering option
Transaction based/ take rateMonthlyPreferred Recipient pricing for corporate clients
Transaction based/ take ratePay-as-you-goAd Hoc Recipient pricing for irregular orders

Go-to-market motion1 record

Distribution channels4 records

Marketing channels4 records

Prodo Laboratories product offering

Product offering

Core offering

Prodo Laboratories operates a service business providing high-quality human pancreatic islets (including normal and Type 2 diabetes donor islets) to biotechnology and pharmaceutical companies for in vitro and in vivo diabetes drug development testing, and to academic and government-funded researchers for diabetes research. It also produces and sells a proprietary cGMP islet culture media product line (Prodo Islet Media / PIM®) — including recovery, standard culture, and transport media plus required supplements — used by islet researchers globally.

Product overview

Prodo Laboratories is a biotechnology company providing a comprehensive portfolio of products and services for the diabetes research community. The core offering consists of the proprietary cGMP Prodo Islet Media (PIM®) product line, which includes three specialized media formulations—PIM(R)® for recovery, PIM(S)® for standard long-term culture, and PIM(T)® for transport/cold storage—along with required supplements PIM(ABS)® (Human AB Serum), PIM(G)® (Glutamine/Glutathione), and PIM(3X)® (Triple Antibiotics), available individually or as the combined PIM Complete solution. The company also provides Human Islets for Research (HIR) as its primary service, Animal Islets for Research (AIR) including rodent and porcine preparations, and the Islet Testing Authority (ITA) certification service for testing biological reagents on human islets. Contract research services and scientific consulting from Dr. David Scharp complement the product portfolio.

Differentiator

Problem solved

Functional benefit

Brands

  • Prodo Islet Media (PIM): cGMP islet media product line including PIM(R) for recovery, PIM(S) for standard culture, and PIM(T) for transport.
  • Human Islets for Research (HIR)
  • Animal Islets for Research (AIR)
  • Islet Testing Authority (ITA)

Products and services

  • PIM(R)® — Islet Recovery Medium Islet-specific recovery medium manufactured under cGMP conditions, designed for the first 48 hours of tissue culture at 37°C to accelerate recovery of islets following processing and purification. Demonstrates rapid rounding up with increased glucose responsiveness, insulin content, and suitability for implantation. Contains 5.8 mM glucose and no animal proteins or growth factors. For diabetes researchers using Prodo Labs' islet supply or third-party islets.
  • PIM(S)® — Standard Culture Medium Islet-specific standard culture medium manufactured under cGMP conditions for long-term tissue culture of islets from 2 to 21 days at 37°C. Enhanced with specific components that maintain glucose responsiveness, insulin content, and suitability for implantation. Contains 5.8 mM glucose and 5% Human AB Serum, with no animal proteins or growth factors. For diabetes researchers requiring extended islet culture.
  • PIM(T)® — Transport Medium Proprietary islet medium manufactured under cGMP for cold storage of isolated islets, permitting both short and long-term islet shipping and storage. Provides 3-4 days of cold storage without loss of islet compactness and supports long-term cold tissue culture for approximately 3 weeks. Islets can be directly transferred to tissue culture incubator at 37°C without media removal. For researchers needing to ship or store islets.
  • PIM(ABS)® — Human AB Serum Supplement Required cGMP additive for PIM(R), PIM(S), and PIM(T) islet-specific tissue culture media. Human AB serum collected, screened, and frozen until cGMP manufacturing, including heat inactivation and sterile filtration. All lots screened for compatibility with human islets prior to release. For diabetes researchers using PIM media.
  • PIM(G)® — Glutamine/Glutathione Supplement Required cGMP additive for PIM(R), PIM(S), and PIM(T) islet-specific tissue culture media. Shipped separately as a frozen component to permit extended shelf life. For diabetes researchers using PIM media.
  • PIM(3X)® — Triple Antibiotic Supplement cGMP triple antibiotic mixture required to supplement PIM(R), PIM(S), and PIM(T) for islet culture. Shipped separately as a frozen component to permit extended shelf life. For diabetes researchers using PIM media requiring contamination control.
  • PIM Complete Simplified ordering solution combining base medium (PIM(R)® for Recovery, PIM(S)® for Standard, or PIM(T)® for Transport) and all required supplements (PIM(ABS)® Human AB Serum, PIM(G)® Glutamine/Glutathione, PIM(3X)® Triple Antibiotics) under a single catalog number. For diabetes researchers purchasing the full PIM media system.
  • Human Islets for Research (HIR) Primary service business providing high quality human islets to biotechnology and pharmaceutical companies for in vitro and in vivo testing in diabetes drug development, and to academic and government-funded researchers for diabetes research. Islets sourced from cadaver organ donors with documented informed consent, processed to documented purity of 85-90% and viability of 95%. Includes Type 2 diabetes donor islets (added October 2010). Islets held on tissue culture for 2-3 days for quality assurance before shipping. Available as Preferred Recipient (monthly specified amounts, lower pricing, higher priority) or Ad Hoc Recipient (as-needed) arrangements.
  • Animal Islets for Research (AIR)

Quantifiable outcome

  • Purity averaging 85-90% and viability averaging 95% for shipped human islets
  • +2 more outcomes

Companies that use Prodo Laboratories

Customer profile

Named customers3 records

Segments4 records

Ideal customer profiles5 records

Prodo Laboratories technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature6 records

Prodo Laboratories partnerships and signals

Strategic signal

Partnerships

Eight partnerships are on record, tiered core and minor.

  • Eolas Biosciences Co., Ltd.coreChannel Partner/ Reseller/ DistributorExclusive distributor for Prodo Labs products (islets and media) in Japan. Located at 2-21-18 Kita-Matsudo, Matsudo-shi, Chiba Prefecture 271-0063, Japan. Contact: TEL: +81-47-308-2204, FAX: +81-47-308-2104, www.eolas-bio.co.jp
  • Tebubio (Europe)coreChannel Partner/ Reseller/ DistributorMulti-country European distributor network covering Belgium, Luxembourg, France, Germany, Austria, Switzerland, Italy, Netherlands, Portugal, Spain, UK, Ireland, and Rest of Europe. Offices include Tebubio Belgium & Luxembourg (Lier), Tebubio Sas-France (Le Perray En Yvelines), Tebubio Germany/Austria/Switzerland (Offenbach), Tebubio Italy (Magenta), Tebubio Netherlands (Heerhugowaard), Tebubio Portugal (Lisboa), Tebubio Spain (Barcelona), Tebubio UK & Ireland (Peterborough).
  • Tissue Solutions, Ltd.minorChannel Partner/ Reseller/ DistributorUK-based distributor for Prodo Labs products. Located at Suite 1.2 First Floor, Fleming Pavilion, Todd Campus, West of Scotland Science Park, Glasgow, G20 0XA. Tel: +44 (0)141 299 0055.
  • Scharp-Lacy Research Institute (SLRI)coreStrategic or Co-development PartnerCollaborative partnership where SLRI handles academic distribution of human islets to JDRF and NIDDK funded researchers. SLRI's Islet Testing Authority (ITA) division provides testing and certification services for tissue culture media, reagents, and processing solutions. Formerly known as Invenio Institute; name changed in June 2008 to honor Paul Lacy and David Scharp's collaborative research history.
  • National Institute for Diabetes, Digestive, and Kidney Diseases (NIDDK)coreStrategic or Co-development PartnerPartnership through Interactive Islet Distribution Program (IIDP). Prodo Labs is the only corporate laboratory partner, collaborating with SLRI to supply human islets to NIDDK funded diabetes investigators.
  • Juvenile Diabetes Research Foundation (JDRF)coreStrategic or Co-development PartnerJDRF contracted with Invenio Institute (now SLRI) to distribute human islets to JDRF funded investigators. Prodo Labs processes the human islets for this distribution program. Distributed 5 million human islets during first contract in 2007.
  • Organ Procurement Organizations (OPOs)coreOthersContracts with specific Organ Procurement Organizations to deliver human research pancreases from UNOS listed cadaver organ donors refused for primary transplantation. Required criteria include freedom from specific diseases, appropriate blood test and drug screen results.
  • Washington University School of MedicineminorStrategic or Co-development PartnerDr. Scharp trained and worked at Washington University for nearly 30 years. Collaborative studies with late Paul E. Lacy pioneered early progress in islet transplantation. Company founders maintain academic research connections.

Scale indicators8 records

Recent moves7 records

Expansion highlights6 records

Prodo Laboratories competitors and assessment

Company assessment

Emerging players

  • Sernova Corp: Develops Cell Pouch System for islet transplantation in Type 1 diabetes. Adjacent player in diabetes cell therapy research that uses human islets for preclinical testing, creating indirect customer relationship with Prodo Labs' islet supply service.
  • ViaCyte: Develops stem cell-derived islet cell replacement therapies for Type 1 diabetes. While not a direct service competitor, ViaCyte's stem cell-derived beta cells represent a future alternative to cadaver-derived human islets that Prodo Labs supplies for research.
  • Beta-O2 Technologies: Develops encapsulated pancreatic beta cell implants (βAir) for Type 1 diabetes treatment. Operates in the diabetes cell therapy space that intersects with Prodo Labs' human islet research services and shares the same end-research customer base.

Broad incumbents

  • Thermo Fisher Scientific: Major life science tools company producing cell culture media, reagents, and laboratory consumables through brands like Gibco. Overlaps with Prodo Labs' media product line but serves far broader research markets with greater resources and distribution scale.
  • Lonza Group: Global leader in cell and gene therapy manufacturing services and cell culture media production. Comparable to Prodo Labs as a broad incumbent providing cell-based services and biological products to pharma/biotech, though Lonza operates across many therapeutic areas rather than specializing in islets.
  • Merck KGaA (Sigma-Aldrich): Global life science tools giant producing cell culture media, reagents, and laboratory consumables. Competes broadly with Prodo Labs' media products while serving vastly larger and more diversified research customer base.

Direct peers

  • PromoCell: Provides primary human cells, animal cells, and specialized cell culture media for research applications. Direct peer offering comparable cell-based products and culture media to diabetes and broader biomedical research markets.
  • STEMCELL Technologies: Specializes in cell culture media, primary cells, and tissue-specific reagents for life science research. Direct peer to Prodo Labs' islet media business with comparable specialized cell biology products serving research customers.
  • CellGenix: Manufactures cell culture media, cytokines, and reagents for cell and gene therapy applications. Comparable to Prodo Labs' cGMP media manufacturing with focus on regulated cell therapy markets and pharmaceutical customers.
  • Discovery Life Sciences: Provides human biospecimens, including tissues and cells, for biomedical research and drug development. Direct peer offering comparable human tissue procurement, processing, and distribution services to pharma/biotech customers similar to Prodo Labs' islet supply business.

Market position

Strengths5 records

Weaknesses2 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Prodo Laboratories compliance and trust

Trust signal

Compliance2 records

Prodo Laboratories financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Prodo Laboratories leadership team

Management profile

Number of profiles

Profiles3 records

Prodo Laboratories subsidiaries and ownership

Company hierarchy

Subsidiaries1 record

Prodo Laboratories funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Prodo Laboratories M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Prodo Laboratories

What does Prodo Laboratories do?

Prodo Laboratories operates a service business providing high-quality human pancreatic islets (including normal and Type 2 diabetes donor islets) to biotechnology and pharmaceutical companies for in vitro and in vivo diabetes drug development testing, and to academic and government-funded researchers for diabetes research. It also produces and sells a proprietary cGMP islet culture media product line (Prodo Islet Media / PIM®) — including recovery, standard culture, and transport media plus required supplements — used by islet researchers globally.

Is Prodo Laboratories a public or private company?

Prodo Laboratories is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was Prodo Laboratories founded?

Prodo Laboratories was founded in 2006. It employs 11 to 50 people.

Where is Prodo Laboratories based?

Prodo Laboratories is headquartered in Aliso Viejo, United States, in the North America region.

How does Prodo Laboratories make money?

Four revenue lines are on record. Human Islets for Research (HIR) is the primary driver. The others are cGMP Prodo Islet Media Products, contract Research Services and islet Testing Authority (ITA).

Who are Prodo Laboratories's main competitors?

Emerging players on record are Sernova Corp, ViaCyte and Beta-O2 Technologies. Broad incumbents are Thermo Fisher Scientific, Lonza Group and Merck KGaA (Sigma-Aldrich). Direct peers are PromoCell, STEMCELL Technologies, CellGenix and Discovery Life Sciences.

Does Prodo Laboratories have an API?

No public API is recorded for Prodo Laboratories.

What industry is Prodo Laboratories in?

Prodo Laboratories's product category is Diabetes Research Services & Islet Supply. Its primary akta.pro industry code is HLAGANAB, Proteomics & Mass Spectrometry Services. Its NAICS code is 541714 and its SIC code is 2835.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales